Spero Therapeutics Inc (SPRO) Stock AnalysisSPROStock AnalysisSpero Therapeutics Inc

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Spero Therapeutics Inc is not a strong buy at this moment. The current price is $1.20, and the RSI indicates a bearish trend at 38.53, suggesting the stock is oversold. While the company has secured a significant licensing deal worth up to $1.1 billion, its recent earnings report showed zero revenue for Q2 2026 and a net loss of $9.6 million, which raises concerns about its financial stability. The stock has experienced a year-to-date change of -48.94%, indicating substantial declines, and the forward P/E ratio is currently at 0, reflecting uncertainty in future earnings. The main risk is the lack of revenue generation, as evidenced by the zero revenue reported for Q2 2026.

4 analysts cover SPRO: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 4.00.